Breaking News

Financial Report: Bristol-Myers Squibb

July 24, 2014

Results impacted by diabetes divestiture

Bristol-Myers Squibb

2Q Revenues: $3.9 billion (-4%)

2Q Earnings: $334.0 million (-37%)

YTD Revenues: $7.7 billion (-2%)

YTD Earnings: $1.3 billion (+10%)

Comments: U.S. revenues decreased 7% to $1.9 billion in the quarter and International revenues were down 1% to $2.0 billion. Reyataz sales were down 16% to $362 million. The Sustiva Franchise was down 12% to $361 million. Eliquis sales grew by $159 million, Yervoy sales were up 38% to $321 million, Sprycel sales grew 18% to $368 million, and Orencia sales were $402 million, up 14%. R&D expenses were up 49% to $1.4 billion in the quarter and included impairment and acquisition-related charges of $458 million. Results in the quarter were impacted by the divestiture of the diabetes alliance.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision